Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs
- PMID: 30429802
- PMCID: PMC6220073
- DOI: 10.3389/fpsyt.2018.00553
Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs
Abstract
This post-hoc study was aimed at assessing whether disease severity was higher in a sample of Treatment Resistant Schizophrenia patients (TRS) compared to schizophrenia patients responsive to antipsychotics (non-TRS). Determinants of disease severity were also investigated in these groups. Eligible patients were screened by standardized diagnostic algorithm to categorize them as TRS or non-TRS. All patients underwent the following assessments: CGI-S; PANSS; DAI; NES; a battery of cognitive tests. Socio-demographic and clinical variables were also recorded. TRS patients exhibited significantly higher disease severity and psychotic symptoms, either as PANSS total score or subscales' scores. A preliminary correlation analysis ruled out clinical and cognitive variables not associated with disease severity in the two groups. Hierarchical linear regression showed that negative symptoms were the clinical variable explaining the highest part of variation in disease severity in TRS, while in non-TRS patients PANSS-General Psychopathology was the variable explaining the highest variation. Mediation analysis showed that negative symptoms mediate the effects of verbal fluency dysfunctions and high-level neurological soft signs (NSS) on TRS' disease severity. These results show that determinants of disease severity sharply differ in TRS and non-TRS patients, and let hypothesize that TRS may stem from cognitive disfunctions and putatively neurodevelopmental aberrations.
Keywords: antipsychotics; clozapine; positive symptoms; psychosis; refractory; response.
Figures


Similar articles
-
Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables.Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:356-366. doi: 10.1016/j.pnpbp.2017.09.002. Epub 2017 Sep 5. Prog Neuropsychopharmacol Biol Psychiatry. 2018. PMID: 28887181 Clinical Trial.
-
Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients.Schizophr Res. 2018 Dec;202:217-225. doi: 10.1016/j.schres.2018.06.030. Epub 2018 Jun 20. Schizophr Res. 2018. PMID: 29934250 Clinical Trial.
-
Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses.Psychiatry Res. 2013 Dec 15;210(2):387-95. doi: 10.1016/j.psychres.2013.06.042. Epub 2013 Jul 30. Psychiatry Res. 2013. PMID: 23910239
-
Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation.Psychiatry Res. 2012 May 15;197(1-2):1-6. doi: 10.1016/j.psychres.2012.02.013. Epub 2012 Mar 18. Psychiatry Res. 2012. PMID: 22429484 Review.
-
The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research.NPJ Schizophr. 2020 Jan 7;6(1):1. doi: 10.1038/s41537-019-0090-z. NPJ Schizophr. 2020. PMID: 31911624 Free PMC article. Review.
Cited by
-
Plasma neurofilament light chain protein is not increased in forensic psychiatric populations: a pilot study.Front Psychiatry. 2023 May 4;14:1176266. doi: 10.3389/fpsyt.2023.1176266. eCollection 2023. Front Psychiatry. 2023. PMID: 37215673 Free PMC article.
-
Revealing differential psychotic symptoms in schizophrenia and bipolar I disorder by manifold learning and network analyses.Transl Psychiatry. 2025 Jun 6;15(1):194. doi: 10.1038/s41398-025-03403-6. Transl Psychiatry. 2025. PMID: 40481013 Free PMC article.
-
The effect of ultraviolet radiation on the incidence and severity of major mental illness using birth month, birth year, and sunspot data.Heliyon. 2022 Mar 25;8(3):e09197. doi: 10.1016/j.heliyon.2022.e09197. eCollection 2022 Mar. Heliyon. 2022. PMID: 35368522 Free PMC article.
-
Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics.Biomolecules. 2022 Jun 29;12(7):909. doi: 10.3390/biom12070909. Biomolecules. 2022. PMID: 35883465 Free PMC article.
-
Duration Mismatch Negativity Predicts Remission in First-Episode Schizophrenia Patients.Front Psychiatry. 2021 Nov 25;12:777378. doi: 10.3389/fpsyt.2021.777378. eCollection 2021. Front Psychiatry. 2021. PMID: 34899430 Free PMC article.
References
-
- Howes OD, McCutcheon R, Agid O, de Bartolomeis A, van Beveren NJ, Birnbaum ML, et al. . Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry (2017) 174:216–29. 10.1176/appi.ajp.2016.16050503 - DOI - PMC - PubMed
-
- Iasevoli F, Giordano S, Balletta R, Latte G, Formato MV, Prinzivalli E, et al. . Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones. Prog Neuropsychopharmacol Biol Psychiatry (2016) 65:34–48. 10.1016/j.pnpbp.2015.08.010 - DOI - PubMed
-
- Iasevoli F, Avagliano C, Altavilla B, Barone A, Ciccarelli M, D'Ambrosio L, et al. . Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: a study by ROC curve analysis and multivariate analyses. Psychiatry Res. (2018) 269:481–93. 10.1016/j.psychres.2018.08.109 - DOI - PubMed
LinkOut - more resources
Full Text Sources